

PDAC-DM vs LSDM					
	AUC (95% CI)	Sensitivity at 99% specificity	Sensitivity at 97.5% specificity	Sensitivity at 95% specificity	Sensitivity at 90% specificity
AACT(μ g/mL)	0.69 (0.56-0.82)	23.8%	23.8%	28.6%	50.0%
Adiponectin (μ g/mL)	0.78 (0.64-0.92)	8.8%	8.8%	8.8%	14.7%
Adrenomedullin plasma (ng/mL)	0.74 (0.58-0.9)	0.0%	0.0%	0.0%	0.0%
Adrenomedullin serum (ng/mL)	0.63 (0.43-0.83)	6.2%	6.2%	6.2%	15.6%
Apo-A1 (mg/dL)	0.59 (0.44-0.74)	25.0%	25.0%	25.0%	33.3%
C-peptide (pg/mL)	0.82 (0.69-0.95)	15.6%	15.6%	15.6%	37.5%
CA19-9 (U/mL)	0.88 (0.78-0.98)	75.0%	75.0%	86.1%	86.1%
Chemerin (ng/mL)	0.61 (0.47-0.76)	15.0%	15.0%	22.5%	27.5%
Clusterin (ngmL)	0.71 (0.57-0.84)	41.2%	41.2%	41.2%	44.1%
Ghrelin (pg/mL)	0.67 (0.52-0.82)	14.7%	14.7%	14.7%	26.5%
GIP (pg/mL)	0.87 (0.77-0.97)	76.5%	76.5%	76.5%	76.5%
GLP-1 (pg/mL)	0.76 (0.63-0.88)	41.2%	41.2%	41.2%	52.9%
Glucagon (pg/mL)	0.71 (0.57-0.86)	29.4%	29.4%	29.4%	32.4%
IFN-G (pg/mL)	0.7 (0.55-0.85)	22.6%	22.6%	22.6%	32.3%
IL-12 (pg/mL)	0.7 (0.54-0.87)	3.2%	3.2%	3.2%	38.7%
IL-1Ra (pg/mL)	0.69 (0.52-0.86)	0.0%	0.0%	0.0%	43.3%
IL-4 (pg/mL)	0.74 (0.59-0.89)	16.1%	16.1%	16.1%	35.5%
IL-6 (pg/mL)	0.82 (0.67-0.97)	0.0%	0.0%	0.0%	51.5%
IL-7 (pg/mL)	0.7 (0.52-0.87)	9.7%	9.7%	9.7%	22.6%
IL-8 (pg/mL)	0.87 (0.77-0.98)	45.9%	46.6%	47.7%	63.6%
IL-9 (pg/mL)	0.82 (0.69-0.95)	38.7%	38.7%	38.7%	48.4%
Insulin serum (pg/mL)	0.85 (0.74-0.95)	50.0%	50.0%	50.0%	67.6%
Leptin (pg/mL)	0.81 (0.69-0.93)	44.1%	44.1%	44.1%	50.0%
MIP-1A (pg/mL)	0.73 (0.59-0.87)	38.2%	38.2%	38.2%	44.1%
MIP-1B (pg/mL)	0.85 (0.74-0.96)	48.5%	48.5%	48.5%	48.5%
PAI-1 (pg/mL)	0.72 (0.58-0.86)	27.3%	27.3%	27.3%	39.4%
PDGF-BB (pg/mL)	0.71 (0.55-0.88)	6.2%	6.2%	6.2%	34.4%
SPARC (ng/mL)	0.59 (0.42-0.77)	2.9%	2.9%	8.8%	8.8%
Transferrin (mg/mL)	0.62 (0.47-0.76)	10.5%	10.5%	31.6%	36.8%
vWF (mU/mL)	0.87 (0.78-0.96)	51.3%	51.3%	61.5%	74.4%
AUC , Area under the curve; PDAC-DM , pancreatic cancer-associated diabetes; LSDM , long-standing diabetes (>3yr post-diagnosis of DM)					